The ACME Laboratories Ltd. (DSE: ACMELAB)

Market Cap	16.44B
Revenue (ttm)	30.81B
Net Income (ttm)	2.42B
Shares Out	211.60M
EPS (ttm)	11.44
PE Ratio	6.79
Forward PE	n/a
Dividend	3.50 (4.50%)
Ex-Dividend Date	Nov 21, 2024

Volume	590,961
Open	n/a
Previous Close	78.60
Day's Range	77.40 - 79.30
52-Week Range	62.60 - 94.50
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 27, 2024

About The ACME Laboratories

The ACME Laboratories Ltd. manufactures, markets, and distributes generic pharmaceuticals formulation products in Bangladesh. The company offers pharmaceutical products in various therapeutic areas, such as allergic disorders, analgesic, antifribinolytic, anti-infective, antiviral, artificial sweeteners, cardiovascular, central nervous system (CNS), cough and cold, diabetes, eye care, gastrointestinal, gynaecological, hand sanitizers, hormones and steroid, infusion products, musculoskeletal, nasal preparation, respiratory, sex stimulants, skin ...

• Industry: Pharmaceutical Preparations
• Founded: 1954
• Employees: 8,816
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: ACMELAB

Financial Performance

In 2023, The ACME Laboratories's revenue was 26.95 billion, an increase of 12.95% compared to the previous year's 23.86 billion. Earnings were 2.30 billion, an increase of 9.13%.